Pfizer Inc. $PFE Shares Newly Acquired by First Nebraska Trust Co

First Nebraska Trust Co acquired a new stake in Pfizer Inc. (NYSE:PFE) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 104,083 shares of the biopharmaceutical company’s stock, valued at approximately $2,968,000.

A number of other hedge funds have also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC lifted its holdings in Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 509 shares in the last quarter. Keb Asset Management LLC bought a new position in Pfizer in the 2nd quarter worth approximately $26,000. Field & Main Bank purchased a new stake in Pfizer during the 2nd quarter valued at approximately $27,000. Bullseye Investment Management LLC purchased a new stake in Pfizer during the 2nd quarter valued at approximately $28,000. Finally, Timbuktu Capital Management LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $29,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $29.98 on Wednesday. The stock has a market capitalization of $170.85 billion, a PE ratio of 39.44, a P/E/G ratio of 2.08 and a beta of 0.31. The business has a 50 day simple moving average of $28.64 and a two-hundred day simple moving average of $26.84. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. Pfizer Inc. has a 1-year low of $23.62 and a 1-year high of $31.06.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. The business had revenue of $16.58 billion for the quarter, compared to the consensus estimate of $15.85 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company’s revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS. On average, research analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 5.7%. The ex-dividend date is Friday, November 6th. Pfizer’s payout ratio is currently 226.32%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat earnings and revenue expectations, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised its full-year revenue guidance to $62 billion–$64 billion, citing strong performance and momentum in newer and acquired medicines. Pfizer lifts FY26 guidance
• Positive Sentiment: Growth is broadening beyond COVID products: launched and acquired medicines grew 32%, with Eliquis, Padcev, Vyndaqel, Nurtec and Lorbrena among the products highlighted. Pfizer also cited progress in its obesity and oncology programs. Pfizer’s product growth
• Neutral Sentiment: Pfizer appointed company veteran Cecile Guegan permanent CFO after she served as interim CFO. Her experience may support continuity in financial planning and capital allocation, though the appointment alone does not change the company’s outlook. Pfizer appoints Cecile Guegan CFO
• Negative Sentiment: Quarterly revenue was essentially flat year over year as COVID-related demand continued to fall: Paxlovid sales dropped 63% and Comirnaty sales declined 29%. The ongoing transition away from pandemic products leaves investors focused on whether newer medicines can offset those declines. Pfizer Q3 product sales
• Negative Sentiment: Despite the earnings beat and raised guidance, the stock eased. Investor caution may reflect expectations already embedded in the shares and uncertainty about the longer-term payoff from Pfizer’s acquisitions, pipeline and efforts to address upcoming patent expirations. Pfizer’s growth test ahead

Analyst Ratings Changes

PFE has been the topic of several research analyst reports. Scotiabank boosted their target price on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, October 13th. JPMorgan Chase & Co. raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Finally, Cantor Fitzgerald boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Thursday, October 8th. Five investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.65.

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.